Announcements Trials
Browse Landscape

Status

No longer available 1Approved for marketing 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 182Observational 4Expanded_access 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 2

Interventions

elotuzumab 4Bortezomib 4Lenalidomide 3Dexamethasone 3talquetamab 2selinexor 2pomalidomide 2carfilzomib 2Panobinostat 2venetoclax 1ulocuplumab 1plerixafor 1idecabtagene vicleucel 1fludarabine phosphate 1daratumumab 1ceritinib 1belantamab mafodotin 1Whole-Body Irradiation 1Tacrolimus 1Prednisone 1Mycophenolic Acid 1Melphalan 1Cytarabine 1Crizotinib 1Cord Blood Stem Cell Transplantation 1Calcium Dobesilate 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Expanded_access × carfilzomib × Plasma cell × Clear all
NCT01410500 2017-05-02

Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease

Amgen

Approved for marketing
Plasma cell

Multiple Myeloma

NCT00999414 2015-10-26

2009-32

University of Arkansas

No longer available
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡